Sage Therapeutics, Inc. (SG7.F)

38,51 -0,92 (-2,33%) Börsenschluss: 03:59PM CEST

Sage Therapeutics, Inc.

215 First Street
Cambridge, MA 02142
United States
617 299 8380
https://www.sagerx.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 689

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Barry E. Greene	Pres, CEO & Director	1,25M	N/A	1963
Ms. Kimi E. Iguchi CPA	CFO & Treasurer	621,17k	1,46M	1962
Dr. Albert J. Robichaud Ph.D.	Chief Scientific Officer	661,68k	N/A	1961
Mr. Christopher Benecchi	Chief Bus. Officer	389,35k	N/A	1972
Mr. Matt Lasmanis	Chief Technology & Innovation Officer	N/A	N/A	N/A
Helen Rubinstein	Investor Relations Officer	N/A	N/A	N/A
Ms. Anne Marie Cook Esq.	Sr. VP, Gen. Counsel & Sec.	N/A	N/A	1962
Ms. Erin E. Lanciani	Chief People & Experience Officer	N/A	N/A	1969
Dr. Amy Schacterle Ph.D.	Sr. VP of R&D Strategy and Bus. Management	N/A	N/A	N/A
Dr. Jim Doherty Ph.D.	Chief Devel. Officer	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2021 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; zuranolone, a neuroactive steroid, which has completed Phase III clinical trials for treating PPD and major depressive disorders, as well as is in Phase II clinical trials for treatment resistant depression, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. Its product pipeline also comprises SAGE-689 that is in Phase II clinical trial for treating acute GABA hypofunction; SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Sage Therapeutics, Inc.s ISS Governance QualityScore, Stand 30. März 2023, lautet 10. Die grundlegenden Scores sind Audit: 7, Vorstand: 9, Shareholderrechte: 8, Kompensation: 10.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.